Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Primary Myelofibrosis Market Expansion From $0.89 Billion In 2026 To $1.14 Billion In 2030
The market for primary myelofibrosis has experienced robust expansion over recent years. Its value is projected to rise from $0.84 billion in 2025 to $0.9 billion in 2026, reflecting a compound annual growth rate of 6.4%. This historical growth was driven by factors such as scarce treatment alternatives, frequent delays in diagnosis and instances of misdiagnosis, insufficient public awareness of the condition, a dependence on traditional therapies, and a relatively limited patient population.
The market for primary myelofibrosis is anticipated to experience robust expansion over the coming years. By 2030, its value is projected to reach $1.14 billion, reflecting a compound annual growth rate (CAGR) of 6.2%. This forecasted growth is driven by factors such as the creation of innovative targeted therapies, a rise in clinical trial initiatives, progress in genetic and molecular diagnostics, increased funding for hematology research, and a greater emphasis on personalized medicine. Key developments expected in this period include heightened awareness and earlier detection of the condition, an expansion of targeted and individualized treatment strategies, broader implementation of sophisticated diagnostic technologies, a surge in clinical trial and research efforts, and a stronger focus on patient support programs and comprehensive disease management.
Download A Free Sample Report For Comprehensive Market Insights:
Primary Myelofibrosis Market Growth Factors Supporting Long-Term Expansion
A rise in the prevalence of myelofibrosis is anticipated to stimulate expansion in the primary myelofibrosis market moving forward. This condition, a rare bone marrow cancer, interferes with the body’s regular production of blood cells, causing significant scar tissue formation in the marrow that leads to serious anemia, weakness, fatigue, and a swollen spleen. The growing frequency of myelofibrosis is largely attributed to an aging demographic, as it commonly affects individuals beyond the age of 60, and extended lifespans are increasing the number of confirmed cases. Higher prevalence rates are enhancing the management of primary myelofibrosis by fueling research efforts, improving early detection, broadening available therapies, and fostering better clinical standards and specialized care approaches. For example, in November 2024, a report from the National Institute for Health and Care Excellence, a UK-based independent public body, indicated that myelofibrosis occurs in 3.2 per 100,000 people in the UK, with an incidence rate of 0.6 per 100,000. Consequently, the increasing occurrence of myelofibrosis is propelling growth in the primary myelofibrosis market.
Primary Myelofibrosis Market Categorization By Product Type And Application
The primary myelofibrosis market covered in this report is segmented –
1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types
2) By Services: Treatment, Diagnosis
3) By Dosage Forms: Solid, Liquids, Other Dosage Forms
4) By Age: Adult, Child, Geriatric
5) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations
2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis
3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders
4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis
Primary Myelofibrosis Market Industry Trends Shaping Future Revenue Growth
Key players in the primary myelofibrosis market are concentrating their efforts on developing advanced treatments, such as Janus kinase 2 inhibiting tablets, with the goal of enhancing symptom management and decelerating disease advancement. These oral medications work by suppressing the activity of the JAK2 enzyme, which plays a central role in the irregular signaling pathways that drive excessive blood cell production in primary myelofibrosis. The tablets contribute to reducing spleen size, easing symptoms like fatigue and bone pain, and slowing the overall progression of the disease. As an example, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotechnology firm based in Korea, introduced Omjjara (momelotinib), a novel therapeutic option for myelofibrosis. This drug has received approval from South Korea’s Ministry of Food and Drug Safety and is designed for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who are also dealing with moderate to severe anemia. Omjjara functions as an oral inhibitor of Janus kinases (JAK1 and JAK2) as well as activin A receptor type 1 (ACVR1), targeting symptoms like anemia, an enlarged spleen, and fatigue. Its authorization is backed by clinical trial results that show considerable enhancements in anemia, spleen size, and overall symptom relief when compared to existing therapies.
Primary Myelofibrosis Market Company Landscape And Strategic Competition
Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.
Access The Complete Primary Myelofibrosis Market Report:
Primary Myelofibrosis Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model